Patents by Inventor Nozomi Katayama

Nozomi Katayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7294475
    Abstract: A protein and DNA encoding the same are useful as preventives/remedies for diseases such as hypoglycemia, etc. The protein of the present invention is also useful as a reagent for screening a compound that inhibits the binding of the protein of the present invention to IRAP (insulin responsive aminopeptidase) or to GLUT4 (glucose transporter 4). The compound that inhibits the binding of the protein of the present invention to IRAP or GLUT4 is useful as a preventive/remedy for diseases, e.g., hyperglycemia, diabetes mellitus, etc.
    Type: Grant
    Filed: February 10, 2006
    Date of Patent: November 13, 2007
    Assignee: Takeda Chemical Industries, Limited
    Inventors: Hideaki Tojo, Nozomi Katayama, Shigeya Kakimoto
  • Patent number: 7247705
    Abstract: The present invention provides proteins having the Na+/glucose transporter activity, DNAs encoding the proteins, a method of screening for a compound enhancing or inhibiting the activity of the proteins, and compounds obtained by the screening method. The proteins having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, 15 or 26 are useful as a diagnostic marker for a disease such as diabetes. The compounds enhancing or inhibiting the activity of the proteins, obtained the screening method using the proteins, can be used as a prophylactic and/or therapeutic agent for a disease such as diabetes and hyperlipidemia.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: July 24, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Keiji Iwamoto, Nozomi Katayama, Mihoko Kawamura
  • Publication number: 20060183158
    Abstract: A protein and DNA encoding the same are useful as preventives/remedies for diseases such as hypoglycemia, etc. The protein of the present invention is also useful as a reagent for screening a compound that inhibits the binding of the protein of the present invention to IRAP (insulin responsive aminopeptidase) or to GLUT4 (glucose transporter 4). The compound that inhibits the binding of the protein of the present invention to IRAP or GLUT4 is useful as a preventive/remedy for diseases, e.g., hyperglycemia, diabetes mellitus, etc.
    Type: Application
    Filed: February 10, 2006
    Publication date: August 17, 2006
    Inventors: Hideaki Tojo, Nozomi Katayama, Shigeya Kakimoto
  • Patent number: 7064106
    Abstract: A protein and DNA encoding the same are useful as preventives/remedies for diseases such as hypoglycemia, etc. The protein of the present invention is also useful as a reagent for screening a compound that inhibits the binding of the protein of the present invention to IRAP (insulin responsive aminopeptidase) or to GLUT4 (glucose transporter 4). The compound that inhibits the binding of the protein of the present invention to IRAP or GLUT4 is useful as a preventive/remedy for diseases, e.g., hyperglycemia, diabetes mellitus, etc.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: June 20, 2006
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Hideaki Tojo, Nozomi Katayama, Shigeya Kakimoto
  • Publication number: 20060063711
    Abstract: The present invention provides an agent that inhibits or promotes glucose uptake in the small intestine, etc., comprising a compound that inhibits or promotes the activity of Na+/glucose transporter (SGLT) homologs.
    Type: Application
    Filed: October 28, 2003
    Publication date: March 23, 2006
    Inventors: Keiji Iwamoto, Nozomi Katayama, Mihoko Kawamura
  • Patent number: 6911468
    Abstract: A compound of the formula (I): wherein X1 and X2 are the same or different and each is a bond or a spacer having 1 to 20 atom(s) in the main chain; one of R1 and R2 is a cycle group having substituent(s) selected from 1) an optionally substituted carboxy-C1-6 alkoxy group and 2) an optionally substituted carboxy-C1-6 aliphatic hydrocarbon group, wherein the cycle group optionally has additional substituent(s), and the other is an optionally substituted cycle group or a hydrogen atom; and R3, R4 and R5 are the same or different and each is a hydrogen atom or a substituent, or R4 may link together with R3 or R5 to form an optionally substituted ring; provided that when R3 is a hydrogen atom, R4 is a hydrogen atom and R5 is methyl, X2—R2 is not 4-cyclohexylphenyl; when R3 is 4-methoxyphenyl, R4 is a hydrogen atom and R5 is methyl, X2—R2 is not 4-methoxyphenyl; and when R1 or R2 is a hydrogen atom, the adjacent X1 or X2 is not a C1-7 alkylene; or a salt thereof exhibits a protein tyrosine phosphatase inhibi
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: June 28, 2005
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Takahiro Matsumoto, Nozomi Katayama, Hiroshi Mabuchi
  • Publication number: 20040072742
    Abstract: A protein and DNA encoding the same are useful as preventives/remedies for diseases such as hypoglycemia, etc. The protein of the present invention is also useful as a reagent for screening a compound that inhibits the binding of the protein of the present invention to IRAP (insulin responsive aminopeptidase) or to GLUT4 (glucose transporter 4). The compound that inhibits the binding of the protein of the present invention to IRAP or GLUT4 is useful as a preventive/remedy for diseases, e.g., hyperglycemia, diabetes mellitus, etc.
    Type: Application
    Filed: June 14, 2002
    Publication date: April 15, 2004
    Inventors: Hideaki Tojo, Nozomi Katayama, Shigeya Kakimoto
  • Publication number: 20040053397
    Abstract: The present invention provides proteins having the Na+/glucose transporter activity, DNAs encoding the proteins, a method of screening for a compound enhancing or inhibiting the activity of the proteins, and compounds obtained by the screening method. The proteins having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, 15 or 26 are useful as a diagnostic marker for a disease such as diabetes. The compounds enhancing or inhibiting the activity of the proteins, obtained the screening method using the proteins, can be used as a prophylactic and/or therapeutic agent for a disease such as diabetes and hyperlipidemia.
    Type: Application
    Filed: June 25, 2003
    Publication date: March 18, 2004
    Inventors: Keiji Iwamoto, Nozomi Katayama, Mihoko Kawamura
  • Publication number: 20030144338
    Abstract: A compound of the formula (I): 1
    Type: Application
    Filed: November 15, 2002
    Publication date: July 31, 2003
    Inventors: Takahiro Matsumoto, Nozomi Katayama, Hiroshi Mabuchi
  • Patent number: 4816559
    Abstract: The iron-containing biologically active peptide TAN-866 produced by microorganisms belonging to the genus Pseudomonas and its iron free compounds have antibacterial activity mainly against gram-negative bacteria. These peptides can be used as a therepeutic agent for bacterial infections in mammals, domestic fowl, etc., caused by Pseudomonas aeruginosa. Further, TAN-866 and its deacyl compounds are also promising as the starting materials and intermediates for the synthesis of novel products.
    Type: Grant
    Filed: July 8, 1987
    Date of Patent: March 28, 1989
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Setsuo Harada, Hideo Ono, Nozomi Katayama